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Background: In HRþ/HER2- early BC, high tumour infiltrating lymphocytes (TIL)
levels predict higher pathological complete response to neoadjuvant chemotherapy,
but are associated with shorter overall survival (Denkert, Lancet Oncol 2018). HRþ/
HER2- BC is a biologically heterogeneous disease, encompassing all BC molecular
intrinsic subtypes, with different clinical behaviour (Cejalvo, CTR 2018). Little is
known concerning the distribution of TIL levels and immune infiltrate composition
across intrinsic subtypes in HRþ/HER2- BC.
Methods: Gene-expression data (Affymetrix platform) from pre-treatment frozen
core-biopsies was available from 66 postmenopausal patients with HRþ/HER2- early
BC from the LETLOB trial (neoadjuvant letrozoleþ/-lapatinib) (Guarneri, JCO 2014).
Intrinsic subtype was assigned using a research-based PAM50 subtype predictor.
Relative leukocyte fractions were calculated using CIBERSORT (Newman, Nature
Methods 2015), a deconvolution method based on RNA gene-expression signatures.
Pre-treatment stromal TILs were assessed on centralized HES slides according to rec-
ommendations (Salgado, Ann Oncol 2015).
Results: Intrinsic subtype distribution was as follows: basal 18% (N¼ 12), HER2-
enriched 8% (N¼ 5), Luminal A 39% (N¼ 25), Luminal B 36% (N¼ 24). Non-lumi-
nal subtypes (HER2-enriched and Basal) had significantly higher baseline TIL levels
than luminal subtypes (median (range): 7 (0-100) and 2 (0-35), respectively;
p¼ 0.038). Non-luminal subtypes also presented higher fractions of CD4 memory acti-
vated T-cells (p¼ 0.018), cd T-cells (p¼ 0.010) and M1 macrophages (p¼ 0.001) and
lower fractions of T-regulatory cells (p¼ 0.002) than luminal subtypes.
Conclusions: In HRþ/HER2- early BC, non-luminal subtypes show higher TIL levels
and a more pro-inflammatory anti-tumour immune infiltrate composition. This
immune heterogeneity across intrinsic subtypes should be considered when analysing
the complex prognostic role of TILs in HRþ/HER2- early BC.
Clinical trial identification: NCT00422903.
Legal entity responsible for the study: University of Padua.
Funding: GlaxoSmithKline funded the clinical trial (LETLOB) including gene-expres-
sion analysis; DOR grants 1721185/17 and 1830512/18 from the University of Padua.
Disclosure:M.V. Dieci: Advisory / Consultancy: EliLilly; Advisory / Consultancy: Genomic Health;
Advisory / Consultancy: Celgene. A. Frassoldati: Advisory / Consultancy: Roche; Advisory /
Consultancy: Novartis; Honoraria (self): Pfizer; Honoraria (self): Novartis; Honoraria (self):
AstraZeneca; Honoraria (self): Roche; Honoraria (self): Eisai. A. Prat: Honoraria (self), Advisory /
Consultancy, Research grant / Funding (institution): Roche; Honoraria (self), Advisory /
Consultancy, Research grant / Funding (institution): Pfizer; Honoraria (self), Advisory / Consultancy,
Research grant / Funding (institution): Novartis; Honoraria (self), Advisory / Consultancy, Research
grant / Funding (institution): Amgen; Honoraria (self), Advisory / Consultancy: BMS; Honoraria
(self), Research grant / Funding (institution): Daiichi Sankyo; Advisory / Consultancy: Puma;
Advisory / Consultancy: Oncolytics Biotech; Honoraria (institution), Research grant / Funding (insti-
tution): Nanostring; Research grant / Funding (institution): Boehringer; Research grant / Funding
(institution): Lilly. P.F. Conte: Honoraria (self), Advisory / Consultancy, Research grant / Funding
(institution): Novartis; Honoraria (self), Advisory / Consultancy: EliLilly; Honoraria (self), Advisory /
Consultancy: AstraZeneca; Advisory / Consultancy: Tesaro; Honoraria (self), Research grant /
Funding (institution): Roche; Honoraria (self), Research grant / Funding (institution): BMS;
Research grant / Funding (institution): Merck-KGa. V. Guarneri: Advisory / Consultancy, Speaker
Bureau / Expert testimony: EliLilly; Advisory / Consultancy, Speaker Bureau / Expert testimony:
Novartis; Advisory / Consultancy, Research grant / Funding (institution): Roche. All other authors
have declared no conflicts of interest.
245P Frequency of germline mutations in women’s cancer susceptibility
genes in a large cohort of Chinese breast cancer patients
N. Liao1, B. Chen1, G. Zhang1, C. Ren1, Y. Wang1, L. Guo1, L. Cao1, L. Wen1, K. Li1, M. Jia1,
C. Li1, H. Mok1, X. Chen1, G. Wei1, J. Lin1, Z. Zhang2, T. Hou2, X. Shi2, H. HanZhang2,
H. Liu2
1Department of Breast Cancer, Guangdong General Hospital, Guangzhou, China,
2Medical Department, Burning Rock Biotech, Guangzhou, China
Background: The prevalence of cancer related germline mutations in unselected
Chinese breast cancer (BC) patients is unknown. Our study aims to examine the
germline mutations prevalence and to investigate the relationship among tumor char-
acteristics, somatic mutations and germline mutations.
Methods: Matched white blood cells and tumor tissue samples of 524 unselected
Chinese BC patients (stage Tis to IV) were profiled using a panel consisting of 520 can-
cer-related genes. Germline mutations of 62 cancer susceptibility genes included all
breast/ovarian cancer-related genes in the US genetic guidelines were assessed.
Results: A total of 76 pathogenic or likely pathogenic (P/LP) germline variants span-
ning 15 genes were detected from 58 patients (11%), with 29 and 38 mutations detected
in BRCA1/2 and other cancer susceptibility genes, respectively. Overall, mutations
detected included 11 BRCA1, 18 BRCA2, 4 MUTYH, 4 PALB2, 3 ATM, 3 BRIP1, 3
CDH1, 3 RAD51C, 2 CHEK2, 2 FANCA, 2 PMS2, 2 TP53, 1 FANCI, 1 FANCL and 1
PTEN. We detected 1968 germline mutations classified as variants of uncertain signifi-
cance spanning all 62 cancer susceptibility genes from 490 patients (93%). We revealed
young age, premenopausal status, and family history of breast/ovarian cancer were
associated with P/LP germline mutations. Interestingly, somatic TP53 mutations were
detected in all patients with P/LP germline BRCA1 mutations (100%, 11/11) and a
majority (67%, 2/3) of patients with likely pathogenic CDH1 mutations. No somatic
TP53 mutation was detected in patients with germline ATM and TP53 mutations.
Somatic PIK3CA mutations were more frequently seen in patients with germline
CDH1 (3/3). A patient with pathogenic germline PALB2 mutation (p.Q921fs) also has
somatic PALB2 mutation (p.D525fs).
Conclusions: Our study derived the prevalence of P/LP germline mutation in 524
Chinese BC patients and 11% were found to have a germline mutation. We explored
the characteristics of tumor somatic mutations in germline mutations carriers, which
provided a better understanding of patients with germline mutations.
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Background: Decision on adjuvant systemic therapy in hormone positive early breast
carcinoma is the only grey area in breast carcinoma management. This study was done
to investigate the concordance between the results of genomic test(Endopredict), artifi-
cial intelligence(Watson For Oncology,WFO) and tumor board decision and implica-
tions of the same in clinical practice.
Methods: This was a triple blinded, prospective study. Decision regarding the adjuvant
systemic therapy was done by the multidisciplinary tumor board (MDT)after reviewing
the pathology reports & the results correlated with Endopredict test reports & artificial
intelligence(Watson for Oncology).
Results: Total of 42 patients included. Mean age was 58.3 years, 71.4% were post-men-
opausal. Breast conservation was done in 47.6%. 64.2% were T1-2N0 stage. Infiltrating
ductal carcinoma was major type (83.3%). Decision by MDT to give adjuvant chemo-
therapy was for 25 patients (59.5%) & hormonal therapy for rest. Recommendation by
Watson for oncology was to give adjuvant chemotherapy in 50%. Endopredict score
(EPclin) resulted in a low-risk group of 22 patients (52.3%), while 15(47.6%) had a
high risk EPclin score. Discordance between the endopredict test, Watson & tumor
board was for 11 patients (26.1%): 3 patients had high risk score, but the tumor board
decision was to give hormonal therapy due to the age factor. 8 patients had low risk
score, but tumor board decision was to give adjuvant chemotherapy. Extremes of age,
premenopausal status, intermediate grade & high Ki 67% values were the factors associ-
ated with discordance. The treatment decision changed for 4 patients (4/11, 36%) after
reviewing the endopredict test and Watson recommendation.
Conclusions: Tumor board decision can be more scientific & evidence based with the
help of genomics & a learnt colleague in the form of Watson for Oncology. Even though
the clinical experience is the important determinant of adjuvant therapy, genomic test
with artificial intelligence, which includes the scientific evidence, will guide in decision
making. Long term follow up is needed for the validation in our clinical setting.
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